<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166622">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02066298</url>
  </required_header>
  <id_info>
    <org_study_id>AsthmaNet 007</org_study_id>
    <secondary_id>1U10HL098115</secondary_id>
    <nct_id>NCT02066298</nct_id>
  </id_info>
  <brief_title>Steroids In Eosinophil Negative Asthma</brief_title>
  <acronym>SIENA</acronym>
  <official_title>Steroids In Eosinophil Negative Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because approximately half of all mild-moderately-severe asthma is persistently
      non-eosinophilic, it is important to determine prospectively if patients who are
      persistently non-eosinophilic differ in their benefit from inhaled corticosteroid treatment
      compared to patients who are not persistently non-eosinophilic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SIENA is a 42-week randomized, stratified, 3-period double-blind placebo-controlled
      crossover study of patients with symptomatic mild-to-moderate asthma, not already taking an
      inhaled corticosteroid, in whom the effect of &quot;medium-dose&quot; inhaled corticosteroid (ICS)
      will be compared with the effect of placebo and with a long-acting muscarinic antagonist
      (LMA).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary outcome is a composite measure that uses treatment failures, asthma control days, and percent predicted FEV1.</measure>
    <time_frame>End of 12-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of treatment failures. If one treatment results in no treatment failures and another treatment does, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by treatment failures, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment. If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period. If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment. If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone 220mcg BID, followed by Titropium Respimat 5mcg QD, followed by Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone 220mcg BID</intervention_name>
    <description>Mometasone is an ICS</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <other_name>Asmanex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Respimat 5mcg QD</intervention_name>
    <description>Tiotropium is a LMA</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician-diagnosed asthma for at least previous 12 months.

          -  Able to perform reproducible spirometry.

          -  Baseline FEV1≥70% of predicted.

          -  Asthma confirmed either by:

               -  Beta-agonist reversibility to 4 puffs albuterol ≥ 12% OR

               -  Methacholine PC20 ≤ 16 mg/ml

          -  At least 1 of the following indications for chronic controller therapy:

               -  Asthma Symptoms &gt; 2 days/week  OR

               -  Nocturnal Asthma Symptoms &gt; 2 nights/month OR

               -  Short-acting beta-agonist use for symptom control &gt; 2 days/week

          -  For participants ≥18 years of age: Ability to provide informed consent. For
             participants under 18 years of age: Ability to provide verbal or written assent and
             ability of parent to provide informed consent.

          -  Willingness, if female and able to conceive, to utilize one medically-acceptable form
             of contraception.

        Exclusion Criteria:

          -  Chronic inhaled or oral corticosteroid therapy.

          -  Use of inhaled or oral corticosteroid therapy within 6 weeks.

          -  New allergen immunotherapy within the past 3 months or anticipated changes to an
             ongoing immunotherapy regimen.

          -  Use of omalizumab within 3 months.

          -  History of:

               -  bladder-neck obstruction, urinary retention or benign prostatic hyperplasia

               -  narrow angle glaucoma

               -  significant cardiovascular disorders and arrhythmias

               -  life-threatening asthma requiring treatment with intubation or mechanical
                  ventilation within the past 5 years

          -  Respiratory tract infection within past 6 weeks.

          -  History of smoking within the past 1 year, or &gt; 10 pack-years total if ≥ 18 years of
             age, or &gt; 5 pack-years total if &lt; 18 years of age.

          -  Chronic diseases or medical conditions (other than asthma) that could put the
             participant at risk by participation, e.g. chronic diseases of the lung (other than
             asthma), heart, liver, kidney, endocrine or nervous system, or immunodeficiency.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Busse, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Mauger, PhD</last_name>
    <email>dtm5@psu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona College of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital, Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://asthmanetresearch.org/</url>
    <description>AsthmaNet</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>dave mauger</investigator_full_name>
    <investigator_title>Principal Investigator, AsthmaNet Data Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Mometasone</keyword>
  <keyword>Tiotropium</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mometasone furoate</mesh_term>
    <mesh_term>Tiotropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
